Navigation Links
BioMS Medical updates University of Alberta equity position
Date:4/30/2010

contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces 2009 Year End Results
2. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. BioMS Medical provides corporate update
5. BioMS Medical Announces Third Quarter 2009 Results
6. BioMS Medical announces second quarter 2009 results
7. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
8. BioMS Medical to participate in panel session at Bio International Convention 2009
9. BioMS Medical Announces First quarter 2009 results
10. BioMS Medical to present at Alberta Economic Forum in Geneva
11. BioMS Medical to present at BioFinance 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
(Date:9/2/2015)... 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a ... and related conditions, announced today that it has closed ... note financing, raising a total of $5.175 million, which ... Josh Disbrow , Chief Executive ... are intended to be used to conduct clinical studies ...
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... 2011 Reportlinker.com announces that a new market ... Cell Therapy - Technologies, Markets and ... SummaryThis report describes and evaluates cell ... to play an important role in the practice ...
... Cord Blood America, Inc . (OTC Bulletin Board: ... America,s CEO and Co-Founder Matthew Schissler has been named chairman ... Biotech Committee is charged with developing programs and initiatives to ... existing biotech companies expand in the area. ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) announced ... has granted fast track designation for carfilzomib, a next ... with relapsed and refractory multiple myeloma. The Fast Track ... the development, and expedite the review of drugs to ...
Cached Biology Technology:Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 2Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 3Cord Blood America CEO and Co-Founder Matthew Schissler Named Chairman of Biotech Committee for Nevada Development Authority 2Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 2Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 3Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 4
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... Marginal lands those unsuited for food crops can ... energy production goals. In the current issue of ... University shows that marginal lands represent a huge untapped resource ... fuel production, which could annually produce up to 5.5 billion ...
... Calif. ( www.ucr.edu ) An assistant professor at ... is using the teeth of a marine snail found ... and more efficient nanoscale materials to improve solar cells ... David Kisailus, an assistant professor of chemical and environmental ...
... State University,s Biodesign Institute has announced a partnership ... next phase of a multi-million-dollar, multi-institutional research project ... an individual,s exposure to radiation in the event ... a $9.33 million contract option as part of ...
Cached Biology News:Marginal lands are prime fuel source for alternative energy 2Using snail teeth to improve solar cells and batteries 2Using snail teeth to improve solar cells and batteries 3ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose 2
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
... an easy-to-use siRNA transfection reagent that has ... in a variety of cell lines. jetSI-ENDO ... optimized, straightforward protocol. High levels of gene ... transfection of 20 to 100 nM of ...
Biology Products: